Perrigo announces patent litigation settlement for generic version of Nascobal® spray
Perrigo announced that it has settled its Hatch-Waxman litigation relating to Nascobal® (Cyanocobalamin) Nasal Spray brought by Endo Pharmaceuticals. Terms of the settlement are confidential. Annual market sales for the 12-months ending June 2019 were $90 million as measured by IQVIA™. August 21, 2019